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Background: Components of carotid atherosclerotic plaques can reliably be identified and quantified using high
resolution in vivo 3-Tesla CMR. It is suspected that lipid apheresis therapy in addition to lowering serum lipid levels
also has an influence on development and progression of atherosclerotic plaques. The purpose of this study was to
evaluate the influence of chronic lipid apheresis (LA) on the composition of atherosclerotic carotid plaques.
Methods: 32 arteries of 16 patients during chronic LA-therapy with carotid plaques and stenosis of 1–80% were
matched according to degree of stenosis with 32 patients, who had recently suffered an ischemic stroke. Of these
patients only the asymptomatic carotid artery was analyzed. All patients underwent black-blood 3 T CMR of the
carotids using parallel imaging and dedicated surface coils. Cardiovascular risk factors were recorded. Morphology
and composition of carotid plaques were evaluated. For statistical evaluation Fisher’s Exact and unpaired t-test were
used. A p-value <0.05 was considered statistically significant.
Results: Patients in the LA-group were younger (63.5 vs. 73.9. years, p<0.05), had a higher prevalence of
hypercholesterolemia and of established coronary heart disease in patients and in first-degree relatives (p<0.05,
respectively). LA-patients had smaller maximum wall areas (49.7 vs. 59.6mm2, p<0.05), showed lower prevalence of
lipid cores (28.1% vs. 56.3%, p<0.05) and the lipid content was smaller than in the control group (5.0 vs. 11.6%,
p<0.05). Minimum lumen areas and maximum total vessel areas did not differ significantly between both groups.
Conclusion: Results of this study suggest that, despite a severer risk profile for cardiovascular complications in
LA-patients, chronic LA is associated with significantly lower lipid content in carotid plaques compared to plaques
of patients without LA with similar degrees of stenosis, which is characteristic of clinically stable plaques.
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Cardiovascular events, such as myocardial infarction or
stroke are the leading cause of death in the western
world. The incidence of cardiovascular diseases like is-
chemic stroke or infarction of heart muscle tissue is well
correlated with a number of risk factors. Dyslipidemia is* Correspondence: tobias.saam@med.lmu.de
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reproduction in any medium, provided the orone of the most important established risk factors being
causally related to cardiovascular events [1].
It has been shown that lowering of pathologically high
serum levels of low density lipoprotein cholesterol (LDL-C)
either by pharmacotherapy or lipid apheresis therapy sig-
nificantly reduces cardiovascular morbidity and mortality
[2,3]. However, how exactly this positive effect is achieved
on a pathophysiological level is not completely understood.
One possible explanation is the improvement of rheo-
logical properties of the blood after lipid loweringLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ciated with increased inflammatory activity in vessel
walls and reduced vasodilatory activity [5,6]. It has also
been suspected that lipid lowering therapy in dyslipi-
demic patients leads to regression of atherosclerotic dis-
ease and reduction of the lipid component of
atherosclerotic plaques [7,8].
Large vessel atherosclerotic disease is considered re-
sponsible for 20–30% of ischemic strokes [9]. It has been
shown that cardiovascular events are correlated not only
with the degree of stenosis of the respective vessel but
even more so with the properties of the stenosing plaque
[10], which promoted the concept of the complicated or
vulnerable plaque [11,12]. One of the key features of the
so-called vulnerable plaques is the large lipid/necrotic
core covered by a thin fibrous cap [11,12]. This leads to
the hypothesis that a decrease in their lipid content sta-
bilizes atherosclerotic plaques.
Lipid apheresis therapy is an effective therapeutic op-
tion to lower serum lipid levels in patients with extensive
hyperlipidemia, where medication alone is insufficient to
reduce serum lipids to target levels [13]. A decrease of
the size of atherosclerotic plaques and possible beneficial
change of their composition have been reported in dysli-
pidemic patients under lipid lowering therapy [7,14,15].
It has been suspected that dyslipidemia is associated
with an increased prevalence of soft plaques [16]. Conse-
quently, a decrease in serum lipid levels should have an
influence on prevalence of soft plaques and plaque com-
position [17] and may lower the fraction of vulnerable
plaques among atherosclerotic lesions [8,18]. This mech-
anism should as well be relevant in lipid apheresis possibly
caused by a direct lowering effect on the lipid content of
atherosclerotic plaques [19]. This might offer an add-
itional explanation for the observed decrease of cardio-
vascular events during chronic lipid apheresis.
A number of techniques allow for the assessment of
atherosclerotic disease, among these extra- and intravas-
cular ultrasound, CT-angiography, conventional angiog-
raphy and cardiovascular magnetic resonance (CMR)
plaque imaging. CMR plaque imaging has become one
of the most reliable techniques to assess atherosclerotic
plaque morphology and composition in good correlation
with histopathology [20,21]. It is non-invasive, involves
no ionizing radiation and is well suited to reliably detect
and quantify plaque components including the lipid con-
tent of atherosclerotic plaques [22].
Existing studies have evaluated the effect of lipid lower-
ing pharmacotherapy on atherosclerotic plaque develop-
ment using CMR [7] or the effect of lipid apheresis on
coronary plaque composition using ultrasound [23]. Other
studies evaluated coronary plaque composition in relation
to serum lipid levels using computed tomography angiog-
raphy [17]. One Study evaluated the development of aorticatherosclerotic plaques in relation to serum lipid levels in
rabbits using CMR [24]. To our knowledge, no studies
have evaluated the effect of chronic lipid apheresis on ca-
rotid atherosclerotic plaque composition using CMR
plaque imaging in human patients.
The purpose of this prospective comparative cross
sectional study was to evaluate the influence of chronic
lipid apheresis (LA) on the composition of atheroscler-
otic carotid plaques using high resolution in vivo 3-Tesla
CMR with parallel imaging techniques.
Methods
Patient selection
A total of 48 patients were enrolled in this prospective cross
sectional, monocentric observational study, which has been
approved by the local institutional ethics committee. In the
chronic lipid apheresis group we examined 32 arteries of 16
patients who had been treated by chronic lipid apheresis
for more than 5 years (7 patients by heparin mediated
plasma precipitation in acidic milieu (HELP ©), 7 patients
by temperature optimized double-filtration plasmapheresis
(Lipidfiltration ©), 2 patients by polyacrylat full blood ad-
sorption (DALI ©)). Indication for chronic lipid apheresis
was severe therapy refractory hypercholesterolemia (N=13)
or isolated Lp(a) hyperlipoproteinemia with progressive
vascular disease (N=3). Lipid apheresis treatment had been
performed in intervals between 3 and 14 days. In the con-
trol group we included 32 consecutive patients matched
for the degree of vascular stenosis, who had recently suf-
fered an ischemic stroke. Of these patients only the asymp-
tomatic artery contralateral to the ischemic stroke was
included. The majority of patients from the lipid apheresis
group (9 out of 16, 56%) and control group (20 out of 32,
63%) received lipid lowering medication at the time of
examination. Manifest coronary artery disease and cardio-
vascular risk factors including serum lipid levels, arterial
hypertension, active or past nicotine abuse, diabetes melli-
tus, family history of coronary artery disease and body mass
index (BMI) were recorded. Values for LDL and Lp (a) for
the lipid apheresis group are given as mean levels calcu-
lated as proposed by Kroon et al. [25]. Other serum lipid
levels for the lipid apheresis group are given as average of
measurements before and after apheresis therapy. Serum
lipid levels for the control group were measured at the
time of the CMR examination performed at time of admis-
sion due to acute ischemic stroke.
MR imaging protocol
All subjects underwent a carotid black-blood high reso-
lution CMR at 3.0-Tesla on a Siemens Verio Scanner
(Siemens AG, Erlangen, Germany) using surface coils
(Machnet, Elde, Netherlands) and a previously published
multi-sequence protocol [26] (time-of-flight MR angiog-
raphy (TOF), axial fat suppressed pre- and post- contrast
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in-plane resolution 0.5 × 0.5 mm2). Parallel imaging based
on the generalized autocalibrating partially parallel acqui-
sition (GRAPPA) algorithm was used for all sequences
with a parallel acquisition technique (PAT) acceleration
factor of 2. Total imaging time was 17:43 minutes. Gado-
butrol (GadovistW, Bayer Schering, Leverkusen, Germany)
of 0.1 mmol/kg (0.1 ml/kg) was given at a rate of 3 ml/s.
Post-contrast T1w imaging was performed approximately
5 minutes after intravenous injection of the contrast
agent. Each scan covered 30 mm (2 mm slice thickness ×
15 matched images across the 5 sequences).Image analysis
An image-quality rating (4-point scale, 1 = non-diagnostic,
2 = poor, 3 = good, 4 = excellent) was assigned to all MR
images. MR data were then independently reviewed by
two experienced radiologists (T.S. and J.G.) who where
blinded regarding the clinical status of the patient. In
case of discrepancy, a consensus decision was made.
Atherosclerotic plaques in the carotid arteries were
recorded and classified according to the modified criteria
of the American Heart Association [27]. For definition of
a complicated AHA-LT6 plaque, at least one of the fol-
lowing three criteria was required: fibrous cap rupture,
intraplaque hemorrhage, juxtaluminal hemorrhage/mural
thrombus. Area measurements of the lumen, outer wall,
and tissue components were obtained using a custom-
designed image analysis tool CASCADE (University of
Washington, Seattle, USA). Tissue components (lipid-rich
necrotic core, calcification, hemorrhage) were identified
based on previously published criteria [20]. The “total
vessel area” included the lumen and wall areas. The nor-
malized wall index (NWI) was calculated by dividing the
wall area by the total vessel area.Statistical analysis
For statistical comparison of the patients with and with-
out lipid apheresis therapy, the Mann–Whitney test with
correction for ties was used for variables describing
frequencies of plaque features, which had skewed distri-
bution. For continuous variables, the Student unpaired
t-test with equal or unequal variances (as appropriate)
was used. To compare clinical demographics between
both groups, Fisher’s exact test was used for categorical
variables, and the unpaired t-test was used for continu-
ous variables. Categorical variables are presented as abso-
lute and relative frequencies, while continuous variables
are presented as mean and standard deviation. Tissue
components were calculated as percentages of the vessel
wall. Analyses were carried out in SPSS for Windows
(version 14.0, IBM, Chicago, IL). A p-value of <0.05 was
considered as statistically significant.Results
Clinical data
Patients in the lipid apheresis group were younger
(63.5 vs. 73.9 years, p<0.05) and had a higher prevalence
of hypercholesterolemia (100% vs. 53%), coronary artery
disease and/or family history of coronary artery disease
(100% vs. 34%) (all p-values <0.05). Total cholesterol
(148.8 vs. 200.8 mg/dl) and LDL (94.7 vs. 128.3 mg/dl) -
averaged as described above - were significantly lower in
the lipid apheresis group than in the control group
(p<0.001). Consequently, LDL/HDL was also lower in
the lipid apheresis group (2.0 vs. 2.8; p<0.01). No further




48 out of 50 scans (96.0%) had a sufficient image quality
(image quality ≥ 2), with an average image quality rating
of 3.6 for the lipid apheresis patients and 3.4 for the con-
trol group (p = ns). The two excluded scans were scans
of the control group. All data are given for 16 lipid
apheresis patients and 32 patients of the control group.
Imaging examples are given [Figures 1 and 2].
Qualitative and quantitative plaque imaging characteristics
Patients in the lipid apheresis group showed a lower
prevalence of lipid cores compared to the control sub-
jects (28.1 vs. 56.3%; p<0.05). The maximum lipid con-
tent as percentage of the vessel wall was also smaller in
the lipid apheresis group (5.0 vs. 11.6%, p<0.05). There
was a tendency towards larger minimum lumen areas in
the lipid apheresis group compared to the control group,
however, both parameters did not differ significantly be-
tween the two groups (15.9 vs. 13.0 mm2, p=ns). The
normalized wall index and the maximum wall area were
smaller in the lipid apheresis group than in the control
group (0.61 vs. 0.72; p<0.001 and 49.7 vs. 59.6 mm2;
p<0.05). Prevalence of plaque calcifications and calcifica-
tion content did not differ between both groups. Intra-
plaque hemorrhage prevalence and hemorrhage content
did not differ significantly between both groups (9.4% vs.
15.6% and 2.1 vs. 2.3%; p=ns), although there was a ten-
dency towards a higher prevalence of hemorrhages in
the control group [Table 2].
AHA lesion type distribution
AHA lesion type IV/V, which is characterized by the
presence of a lipid core covered by a fibrous cap, was
found significantly more often in the control group com-
pared to the lipid apheresis group (38% vs. 13%; p<0.05).
No other significant differences were found although
there was a tendency towards a higher prevalence of cal-
cified AHA type VII lesions in the lipid apheresis group
Table 1 Cinical data
Parameter Lipid apheresis group Control group p-value*
(n=16 patients) (n=32 patients)
Age ± 1 SD [years] 63.5 ± 9,1 73.9 ± 9.2 <0.05
Male [%] 68,8% 84.4% ns
Body Mass Index 26.5 ± 4.4 25.1 ± 5.3 ns
Established CAD [%] 100% 21.9% <0.001
Risk Factors
Hypercholesterolemia [%] 100% 53.3% 0.008
Arterial Hypertension, [%] 75% 68.8% ns
Active Nicotine Abuse [%] 6.3% 28.1% ns
Former Nicotine Abuse [%] 50% 40.7% ns
Diabetes Mellitus [%] 18.8% 21.9% ns
Family History of CAD or CVD [%] 68.8% 34.4% 0.03
Serum Lipids
Total Cholesterol [mg/dl] 148.8 ± 37.7 200.8 ± 47.1 <0.001
Triglycerides [mg/dl] 139.1 ± 93.9 142.0 ± 73.5 ns
LDL [mg/dl] 94.7 ± 28.9 128.3 ± 35.8 <0.001
VLDL [mg/dl] 18.6 ± 7.9 22.4 ± 10.4 ns
HDL [mg/dl] 49.3 ± 12.7 48.2 ± 9.2 ns
LDL/HDL 2.0 ± 1.0 2.8 ± 0.8 0.008
Lipoprotein (a) [mg/dl] 59.9 ± 66.6 47.4 ± 49.4 ns
Two-sided Fisher’s Exact Test or unpaired t-test; SD=Standard Deviation; CAD=Coronary Artery Disease; CVD=Cerebrovascular Disease (TIA or Stroke). Values for
LDL and Lp (a) for the lipid apheresis group are given as mean levels calculated as proposed by Kroon et al. [25]. Other serum lipid levels for the lipid apheresis
group are given as average of measurements before and after apheresis therapy.
ca b 
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Figure 1 Imaging example Lipid Apheresis Group. shows axial TOF (a), T1w without (b) and with (c) contrast agent, PD (d) and T2w (e) MR-
images of an American Heart Association Type II plaque in the right internal carotid artery of a patient from the lipid apheresis group. This plaque
is mainly calcified (arrow); no lipid necrotic core can be seen. The fibrous cap appears intact (arrowhead).





Figure 2 Imaging Example Control Group. shows an American Heart Association type V plaque at the bifurcation in the right internal carotid
artery of a patient from the control group in axial TOF (a), T1w without (b) and with (c) contrast agent, PDw (d) and T2w (e) MR-images. The
plaque consists mainly of a necrotic lipid core without contrast enhancement (arrow) and no relevant calcification.
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[Figure 3].
Discussion
This cross-sectional study showed that patients who
had been treated by chronic lipid apheresis therapy for
more than 5 years had a significantly lower prevalence
of lipid-rich plaques and lower plaque lipid content
compared to asymptomatic arteries with similar degrees
of stenosis. Patients on chronic lipid apheresis therapy
had a lower wall area and a tendency towards more
calcified plaques compared to the control group. Ac-
cordingly, total cholesterol, LDL and LDL/HDL were
lower in the lipid apheresis group suggesting an influ-
ence of these parameters on plaque characteristics. Pla-
ques of patients during chronic lipid apheresis showed
characteristics of more stable plaques compared to the
control group. This study also demonstrated significant
differences in AHA lesion type distribution. AHA lesion
type IV/V, characterized by a lipid core covered by a
fibrous cap was significantly more common in the
control group, whereas the relatively stable calcified
AHA lesion type VII had a higher prevalence in the
lipid apheresis group. In summary, these findings sug-
gest a beneficial influence of lipid apheresis therapy on
plaque composition despite the significantly severer
risk profile in the LA-group considering the higherprevalence of hypercholesterolemia and positive family
history of cardiovascular disease in LA-patients.
This result is in accordance with previously published
studies, which suspected a decrease in the lipid compo-
nent of atherosclerotic plaques of patients under lipid
lowering therapy [17,19]. Underhill et al. [23] showed in
a double-blind trial using 1.5-T CMR to image carotid
atherosclerotic plaques at baseline and after 24 months
of rosuvastatin treatment a significant reduction in lipid
rich necrotic core, whereas the overall plaque burden
remained unchanged over the course of 2 years of treat-
ment. The authors concluded that statin therapy may
have a beneficial effect on plaque volume and compos-
ition, as assessed by non-invasive CMR. Results of this
study support the proposition that serum lipid levels
correlate with lipid content of atherosclerotic lesions.
Since lipid rich plaques seem to be a more vulnerable
subgroup of atherosclerotic lesions, a decrease of their
lipid component might help explain the decrease in car-
diovascular incidents [8].
The minimal lumen area as an indirect measurement
of stenosis was similar in both groups. We found smaller
maximum wall areas in the lipid apheresis group and
smaller normalized wall indices, suggesting a lower
plaque burden in this group of patients. This might in
part be explained by previous studies which have not
found a significant increase in vessel lumen area of






Figure 3 AHA Lesion Type Distribution. Visualizes the distribution of American Heart Association (AHA) lesion Types in the Lipid Apheresis and
the Control Group. Note the higher prevalence of lipid rich type IV/V plaques in the Control Group. There also was a tendency toward higher
prevalence of calcified Type VII plaques in the Lipid Apheresis Group.
Table 2 MR-Imaging data
Lipid apheresis group Control group p-value*
(n=32 arteries) (n=32 arteries)
Lumen Area 15.9 ± 6.3 13.0 ± 7.6 ns
[mm2, Minimum]
Wall Area 49.7 ± 11.8 59.6 ± 21.6 0.03
[mm2, Maximum]
Normalized Wall Index 0.61 ± 0.09 0.72 ± 0.12 <0.001
[Maximum]
Outer Wall Area 105.4 ± 28.3 102.0 ± 35.4 ns
[mm2, Maximum]
Plaque Components (quantitative)
Necrotic Lipid Core 5.0 ± 9.4 11.6 ± 13.4 0.025
[% of Vessel Wall, Maximum]
Intraplaque Hemorrhage 2.1 ± 8.8 2.3 ± 6.8 ns
[% of Vessel Wall, Maximum]
Calcifications 4.8 ± 6.0 5.3 ± 6.1 ns
[% of Vessel Wall, Maximum]
Prevalence of Plaque Components
Necrotic Lipid Core [%] 28.1 56.3 0.025
Intraplaque Hemorrhage [%] 9.4 15.6 ns
Calcifications [%] 53.1 56.3 ns
American Heart Association (AHA) Lesion Type
Type I [%] 15.6 12.5 ns
Type III [%] 25.0 15.6 ns
Type IV/V [%] 13.0 37.5 0.023
Type VI [%] 9.4 15.6 ns
Type VII [%] 37.5 18.8 ns
Type VIII [%] 0 0 ns
* Unpaired t-test; SD=Standard Deviation.
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significant decrease in vessel wall area [7].
Although the number of patients enrolled was rela-
tively small, significant differences in atherosclerotic dis-
ease between lipid apheresis patients and the control
group were identified. This study suggests that CMR is a
powerful tool to noninvasively evaluate atherosclerotic
disease systematically across different groups of patients
and populations.
This study achieved diagnostic image quality in 48 out
of 50 scans, demonstrating that this protocol can be suc-
cessfully used in a clinical setting. This drop-out rate of
only 4% is substantially lower than the drop-out rates
reported in recent 1.5 T MR studies, in which up to 33%
of all patients were excluded due to insufficient image
quality [28,29].
Limitations
Although this study shows significant differences in
plaque morphology and lesion type distribution between
the two groups, the number of patients in this study is
relatively small, and a larger study performed in multiple
centers is necessary to confirm these preliminary find-
ings. Furthermore, the cross-sectional design of the study
allows by definition only a snapshot of plaque burden
and composition at one single time point and no definite
conclusions can be drawn on the evolution of plaque
composition over time. Only CMR examinations with
at least average image quality were considered for the
review, resulting in exclusion of two arteries from ana-
lysis. However, this exclusion rate is lower than in pre-
viously published studies [28,29] and should not have
hampered the results. These results were based on a single
imaging modality: CMR. Information gathered from
other well-known imaging techniques, notably measure-
ments of calcifications from computed tomography,
might further illuminate the differences. However, CMR
is generally considered best suited to identify and quantify
atherosclerotic plaque components in the carotid arteries,
shows good correlation with histology for quantitative
measurements, and does not use ionizing radiation. Given
these advantages and the comparative complexity of a
multi-modality study, sole use of CMR was the logical
choice for this study.
Conclusion
Findings of this study suggest that chronic lipid apheresis
therapy is associated with lower cholesterol, LDL and
LDL/HDL as well as a markedly decreased lipid content
in atherosclerotic carotid plaques as assessed by in vivo
CMR as compared to a control group with similar degree
of arterial stenosis. These findings suggest an influence
of cholesterol, LDL and LDL/HDL on plaque charac-
teristics as well as a stabilizing effect of chronic lipidapheresis therapy on carotid plaque composition and
might explain the observed beneficial influence of lipid
apheresis therapy on clinical outcome. In the future, pro-
spective longitudinal studies are needed to confirm these
promising results and to better assess individual plaque
development over time during chronic lipid apheresis.
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